Journal article · 2020

Bispecific Targeting of PD-1 and PD-L1 Enhances T-cell Activation and Antitumor Immunity

Helen Kotanides, Yiwen Helen Li, Maria Malabunga, Carmine Carpenito, Scott W. Eastman, Yang Shen, George Wang, Ivan V. Inigo, David Surguladze, Anthony L. Pennello, Krishnadatt Persaud, Sagit Hindi and 16 more

Cancer Immunology Research, 8(10), 1300–1310 · Published 1 September 2020 · DOI 10.1158/2326-6066.cir-20-0304

View at the publisherCite this paper

In brief

“Bispecific Targeting of PD-1 and PD-L1 Enhances T-cell Activation and Antitumor Immunity” is a 2020 journal article by Helen Kotanides and 27 co-authors, published in Cancer Immunology Research. OpenAlex counts 72 citations as of 18 November 2026. The publisher's version is not open access, and OpenAlex records no free legal copy.

Citations
72
Most cited in
2024 (18)
Field-weighted impact
3.13
References
44
Authors
28

Abstract

The programmed cell death protein 1 receptor (PD-1) and programmed death ligand 1 (PD-L1) coinhibitory pathway suppresses T-cell–mediated immunity. We hypothesized that cotargeting of PD-1 and PD-L1 with a bispecific antibody molecule could provide an alternative therapeutic approach, with enhanced antitumor activity, compared with monospecific PD-1 and PD-L1 antibodies. Here, we describe LY3434172, a bispecific… Read the full abstract at the publisher.

Excerpt. This paper is not open access.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Kotanides, H., Li, Y. H., Malabunga, M., Carpenito, C., Eastman, S. W., Shen, Y., Wang, G., Inigo, I. V., Surguladze, D., Pennello, A. L., Persaud, K., Hindi, S., Topper, M. B., Chen, X., Zhang, Y., Bulaon, D. K., Bailey, T., Lao, Y., Han, B., . . . Kalos, M. D. (2020). Bispecific Targeting of PD-1 and PD-L1 Enhances T-cell Activation and Antitumor Immunity. Cancer Immunology Research, 8(10), 1300–1310. https://doi.org/10.1158/2326-6066.cir-20-0304

MLA 9

Kotanides, Helen, et al. “Bispecific Targeting of PD-1 and PD-L1 Enhances T-cell Activation and Antitumor Immunity.” Cancer Immunology Research, vol. 8, no. 10, 2020, pp. 1300–1310. https://doi.org/10.1158/2326-6066.cir-20-0304.

Chicago

Kotanides, Helen, Yiwen Helen Li, Maria Malabunga, Carmine Carpenito, Scott W. Eastman, Yang Shen, George Wang, et al. 2020. “Bispecific Targeting of PD-1 and PD-L1 Enhances T-cell Activation and Antitumor Immunity.” Cancer Immunology Research 8 (10): 1300–1310. https://doi.org/10.1158/2326-6066.cir-20-0304.

Harvard

Kotanides, H. et al. (2020) ‘Bispecific Targeting of PD-1 and PD-L1 Enhances T-cell Activation and Antitumor Immunity’, Cancer Immunology Research, 8(10), pp. 1300–1310. doi:10.1158/2326-6066.cir-20-0304.

IEEE

H. Kotanides et al., “Bispecific Targeting of PD-1 and PD-L1 Enhances T-cell Activation and Antitumor Immunity,” Cancer Immunology Research, vol. 8, no. 10, pp. 1300–1310, 2020, doi: 10.1158/2326-6066.cir-20-0304.

BibTeX

@article{kotanides2020bispecific,
  title     = {{Bispecific Targeting of PD-1 and PD-L1 Enhances T-cell Activation and Antitumor Immunity}},
  author    = {Kotanides, Helen and Li, Yiwen Helen and Malabunga, Maria and Carpenito, Carmine and Eastman, Scott W. and Shen, Yang and Wang, George and Inigo, Ivan V. and Surguladze, David and Pennello, Anthony L. and Persaud, Krishnadatt and Hindi, Sagit and Topper, Michael B. and Chen, Xinlei and Zhang, Yiwei and Bulaon, Danielle K. and Bailey, Tim and Lao, Yanbin and Han, Bing and Torgerson, Stacy and Chin, Darin and Sonyi, Andreas and Haidar, Jaafar N. Sleiman and Novosiadly, Ruslan D. and Moxham, Christopher M. and Plowman, Gregory D. and Ludwig, Dale L. and Kalos, Michael D.},
  journal   = {Cancer Immunology Research},
  year      = {2020},
  volume    = {8},
  number    = {10},
  pages     = {1300--1310},
  doi       = {10.1158/2326-6066.cir-20-0304},
  url       = {https://doi.org/10.1158/2326-6066.cir-20-0304}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Citations by year

YearCitationsShare of the best year
202011
202166
20221313
20231414
20241818
20251414
202666

Its field-weighted citation impact is 3.13: it has been cited 3.13 times as often as the average work of the same field, type and year (1.00 is the world average).

Topic and keywords

Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers

  • bispecific antibodies
  • PD-1
  • PD-L1
  • immune checkpoint blockade
  • T cell activation
  • antitumor immunity
  • cancer immunotherapy

Work with this paper

Most-cited papers in Medicine

All highly cited Medicine papers

Questions about this paper

How do I cite this paper in APA style?

Kotanides, H., Li, Y. H., Malabunga, M., Carpenito, C., Eastman, S. W., Shen, Y., Wang, G., Inigo, I. V., Surguladze, D., Pennello, A. L., Persaud, K., Hindi, S., Topper, M. B., Chen, X., Zhang, Y., Bulaon, D. K., Bailey, T., Lao, Y., Han, B., . . . Kalos, M. D. (2020). Bispecific Targeting of PD-1 and PD-L1 Enhances T-cell Activation and Antitumor Immunity. Cancer Immunology Research, 8(10), 1300–1310. https://doi.org/10.1158/2326-6066.cir-20-0304

How many times has this paper been cited?

72 times, according to OpenAlex on 18 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

OpenAlex records no free legal copy. Check your library's access, the authors' pages or a repository, or ask the corresponding author for a copy.

Who wrote this paper?

Helen Kotanides, Yiwen Helen Li, Maria Malabunga, Carmine Carpenito, Scott W. Eastman, Yang Shen, George Wang, Ivan V. Inigo, David Surguladze, Anthony L. Pennello, Krishnadatt Persaud, Sagit Hindi and 16 more.

What is the DOI of this paper?

10.1158/2326-6066.cir-20-0304, permanently at https://doi.org/10.1158/2326-6066.cir-20-0304. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 18 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.